Blog
RSS FeedPosted by Michael Wonder on 26 Jun 2022
US seeks pharmaceutical deal with Switzerland to fast-track FDA approvals
27 June 2022 - The Biden administration wants to reach a narrow sectoral trade agreement with the Swiss pharmaceutical industry, ...
Posted by Michael Wonder on 08 Jun 2022
BioCryst announces approval of Orladeyo (berotralstat) by Swissmedic
7 June 2022 - -- BioCryst Pharmaceuticals today announced that Swissmedic has granted marketing authorisation for oral, once-daily Orladeyo (berotralstat) ...
Posted by Michael Wonder on 31 May 2022
Swiss drug prices still soar above European levels
31 May 2022 - Compared with nine other European countries, Switzerland remains a high-price island for medicines, according to an annual ...
Posted by Michael Wonder on 14 May 2022
Hansa Biopharma announces temporary marketing authorisation in Switzerland for Idefirix (imlifidase) in kidney transplantation
13 May 2022 - Idefirix is now granted marketing authorisation within the EU, the U.K., Israel and Switzerland. ...
Posted by Michael Wonder on 26 Apr 2022
Swissmedic has accepted the new oral edarvarone formulation for the treatment of ALS
25 April 2022 - Mitsubishi Tanabe Pharma announced that Swissmedic has accepted the filing for an investigational oral suspension formalation ...
Posted by Michael Wonder on 25 Apr 2022
Swissmedic grants conditional marketing authorisation for Novavax COVID-19 vaccine
13 April 2022 - Nuvaxovid is the first protein-based COVID-19 vaccine authorised for use in Switzerland. ...
Posted by Michael Wonder on 18 Apr 2022
Switzerland approves its first protein-based Covid vaccine
15 April 2022 - Swissmedic announced its approval on Wednesday making Nuvaxovid the first protein-based vaccine to be licensed in Switzerland. ...
Posted by Michael Wonder on 24 Mar 2022
Despite competition, U.S. cancer drug prices rose even as they fell in Germany and Switzerland
24 March 2022 - Even as prices rose substantially in the U.S. over a recent 12 year period, a new ...
Posted by Michael Wonder on 23 Mar 2022
MorphoSys and Incyte announce Swissmedic temporary approval of Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with r/r DLBCL
22 March 2022 - Minjuvi is a new therapeutic option for eligible DLBCL patients in Switzerland addressing an urgent unmet medical ...
Posted by Michael Wonder on 19 Feb 2022
BeiGene announces approval for Brukinsa (zanubrutinib) by Swissmedic for treatment of adult patients with Waldenström’s macroglobulinaemia
17 February 2022 - With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global ...
Posted by Michael Wonder on 14 Feb 2022
Novavax files for conditional marketing authorisation of COVID-19 Vaccine in Switzerland
14 February 2022 - Novavax today announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional marketing authorisation ...
Posted by Michael Wonder on 17 Jan 2022
Swissmedic grants temporary authorisation to Xevudy for COVID-19 patients
14 January 2022 - Corona medication Xevudy from GSK (sotrovimab) granted temporary authorisation in Switzerland ...
Posted by Michael Wonder on 14 Jan 2022
Celltrion wins conditional nod for Regkirona in Switzerland
14 January 2022 - Celltrion said that Swiss Medic, Switzerland’s drug administration, has temporary authorisation for Regkirona (regdanvimab). ...
Posted by Michael Wonder on 29 Dec 2021
Swiss regulator approves Roche-Regeneron COVID-19 drug
27 December 2021 - The Swiss medicines agency, Swissmedic, has given the green light to the monoclonal antibody cocktail Ronapreve developed ...
Posted by Michael Wonder on 29 Dec 2021
Janssen COVID-19 booster shot approved in Switzerland
28 December 2021 - Medicines regulator Swissmedic has approved the booster of the single-dose vaccine from Johnson & Johnson. ...